Friday, September 3, 2010
"The source for European pharmaceutical biotechnology news..."
Looming patent cliffs and shrivelling pipelines have pharma's big players looking for new business models that will allow them to increase their bottom lines.
Sponsors
Platinum Sponsors
Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Marie Shields
Editor NGP Europe
Editor NGP Europe
Tough competition
The battle between generics and branded products has been going on for a long time: the claims and counter claims over Aspirin, for example, have been in process since the early 20th century.06 Aug 2009
You need adobe flash player to view this content
Latest News
-
GlaxoSmithKline defends anti-ageing drugs
Pharmaceutical giant GlaxoSmithKline has defended drugs, which it has financially backed, that claimed to combat age-related diseases.Read more
17/08/2010 13:52
Comments -
Genzyme reports Q2 loss after inventory ...
Genzyme, the US biotech firm that pharma giant Sanofi-Aventis is currently trying to purchase, has reported a second quarter loss after having to write off an additional tranche...Read more
12/08/2010 13:52
Comments -
Novartis Alcon deal approved by regulators
A deal that saw Swiss drugmaker Novartis buy a minority stake in Alcon has received approval from EU regulators making it possible for the company to take ‘full control’ of the...Read more
10/08/2010 13:36
Comments -
Shire profits increase for quarter
British drugmaker Shire, who is currently buying Belgian firm Movetis, has defied analysts’ predictions and increased their revenues by 35 percent over the quarter to US$840...Read more
05/08/2010 11:36
Comments -
MorphoSys to receive Novartis milestone ...
German biotech company MorphoSys has announced that it is to receive a milestone payment from Novartis in connection with a phase one clinical trial of a HuCAL-derived, fully...Read more
02/08/2010 15:58
Comments -
Sanofi-Aventis to takeover Genzyme?
Industry reports indicate that pharmaceutical giant Sanofi-Aventis has approached the board of Genzyme with a takeover bid of US$19 billion (€14.6 billion) for the company.Read more
29/07/2010 13:18
Comments
Editor’s Choice
-
H1N1 pandemic: 'unjustified scare' and waste of...
The handling of the H1N1 pandemic by the World Health Organization (WHO), along with European Union agencies and national governments, resulted in a "waste of large sums of...Read more -
The force is with you
With patent expiries and generic competition on the rise, the pharmaceutical industry is being scrutinised like never before. As a result, sales force effectiveness is taking...Read more -
All change
Raafat Fahim of Nabi Biopharmaceuticals explains why a new, more efficient business model is needed to cope with the increasing challenges facing the industry.Read more -
Hunting down cancer
Tumours continue bypassing cell pathways whilst molecular biologists doggedly try to understand how cancer works. Haren Rupani explains why we are still in our infancy of cancer...Read more -
Getting personal
William Chin tells Natalie Brandweiner how Lilly is using tailored therapeutics to improve outcomes for patients and boost its bottom line.Read more -
Get real
Travis Johnson of the IACC talks to NGP about the global problem of counterfeit pharmaceuticals.Read more
Readers’ Choice
-
Process excellence in master data manage...
It makes sense to analyze and ensure that the foundations of master data governance are solid and provide the business with strong processes to manage and share master data...Read more -
End-to-end clinical trials supply manage...
Stakeholders point to the clinical costs as a barrier to innovation. The FDA has confirmed in its “Critical path report” that “Streamlining Clinical Trials” is one of the key...Read more -
Imaging is key to success in oncology tr...
As defined by the NCI, "Translational research transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications to reduce...Read more -
Emerging importance of health economics ...
Jacco Keja, Managing Director and Practice Leader at Quintiles Consulting, Visiting Professor Life Sciences Pricing, Erasmus University, looks at the emerging opportunities for...Read more -
Riding the wave
The global pharmaceutical industry is facing some tough challenges at the moment: patent expiries, a lack of new blockbusters, and now the ongoing crisis in the financial...Read more -
Building a sustainable biotech business ...
By Willem van Leeuwen – Managing Director QMR TechnologyRead more
Executive Interviews
Enabling greater clinical trial efficiency
Paula Mchale delves into the world of clinical trials and offers her expertise on how technology could enable better efficiency.
Read more
Barriers to successful biopharmaceutical commer...
Mike Ackermann, Vice President of Global Commercial Strategy and Alliance at Quintiles, illuminates the significant barriers to successful biopharmaceutical commercialisation.
Read more
Pharma manufacturing supply chain
Amgen’s Madhavan Balachandran on why persistence is key to implementing an Operational Excellence campaign
Read more
White Papers
NGP Europe Summit: Drug Discovery
1st - 3rd September 2010
The Next Generation Drug Discovery Summit Europe is designed to bridge the growing technological gap between drug discovery and drug development.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.